Advancing the Science

Mayo Clinic Medical Science Blog

Posts (57)

Fri, Feb 10 1:28pm · Mayo Clinic physician-researchers honored by national society

Two Mayo Clinic researchers have been named to the American Society for Clinical Investigation, bringing the total Mayo membership in the honorary society of physician-scientists to 39. Liewei Wang, M.D., Ph.D., a pharmacologist, and Martin Fernandez-Zapico, M.D., a pancreatic cancer biologist, were named to the society from several hundred nominees nationally. The society has 3,000 members.

Read the full news release on the Mayo Clinic News Network.

Learn about the American Society for Clinical Investigation.

Mon, Jan 9 12:31pm · Single Allele Mutation Heightens Risk of Early-Onset Parkinson’s

A collaboration of 32 researchers in seven countries, led by scientists at Mayo Clinic’s campus in Florida, found that a mutation in only one allele of a Parkinson’s gene, known as PINK1, increases the risk of early-onset disease. The finding, published recently in the journal Brain, addresses a longstanding debate about whether individuals need to inherit two copies of the mutation for an early form of the disease to occur.

Wolfdieter Springer, Ph.D.

Wolfdieter Springer, Ph.D.

The familial form of early-onset Parkinson’s, affecting patients as soon as age 45, is known to occur in individuals with mutations in both inherited alleles of the PINK1 (PTEN-induced putative kinase 1) gene. “This study showed that if a person inherits a specific mutation in just one PINK1 allele, the disease could develop at about age 55 or so. By contrast, the most common, nonfamilial forms of Parkinson’s develop at about age 65,” says the study’s senior investigator, Wolfdieter Springer, Ph.D., a neuroscientist at Mayo Clinic’s Florida campus.

Moreover, the study went on to explain how a single mutation in the PINK1 gene affects cells. PINK1 works with another gene, PARKIN, to clean up damaged mitochondria in the body’s cells. A specific mutation (p.G411S) in one allele of PINK1 substantially impairs this “quality control” pathway by causing a structural change in the enzyme that, in turn, inhibits those produced from other healthy PINK1 allele. “This rare mutation has an outsized effect, and the remaining levels of functional PINK1 protein are not enough to cope with damaged mitochondria,” Dr. Springer says. Without a clean-up mechanism, damaged mitochondria accumulate and become toxic, especially within neurons.

The study started with genetic findings when one of the lead authors, Andreas Puschmann, M.D., Ph.D., of the Department of Neurology, Skåne University Hospital, Sweden, was a visiting scientist at Mayo Clinic. Subsequent steps involved a “very effective synergetic” effort of clinical, structural and cell biologists, along with geneticists and data from thousands of affected patients “It took a real international collaboration to solve this puzzle,” he says.

The findings will not only be helpful to patients who want to understand their risk of disease, but also in the potential development of treatment. Dr. Springer’s team is moving ahead to explore how to preserve the enzymes of the PINK1/PARKIN pathway despite the presence of a mutation. “What we’ve learned about the structure-function changes of the enzyme is now helping us pursue drug design that addresses details of the protein on an atomic level,” he says.

This article originally appeared on the Mayo Clinic News Network.

 

Nov 8, 2016 · Becoming a Biomedical Scientist

“I have to tell you that the sheer intellectual joy of finding out how life works is really cool.”         – the late Susan Lindquist, Ph.D., pioneering genetic scientist

This last line from Dr. Lindquist’s obituary in the Sunday New York Times struck me as a timeless statement of enthusiasm and dedication. Dr. Lindquist graduated from Illinois and Harvard and went on to explain how genetic mechanisms work behind such conditions as Parkinson’s and Alzheimer’s.

Just hours after reading the Times, I received the link to the new video about Mayo’s role in creating scientists like Dr. Lindquist. I was thinking of her words as I watched it.

I can assure you, the enthusiasm in this footage is not staged or acted. Everyone and everything is real, including the determination. My colleagues at the Mayo Clinic Graduate School of Biomedical Research have been trying to capture and convey all of this for some time now… I think they just succeeded.

https://youtu.be/7EHkLe-PUr8

Aug 3, 2016 · Mayo Clinic Takes Medical Research to Kilimanjaro

mount-kilimanjaro-tanzaniaThe core group of Mayo Clinic researchers that moved their lab to the base camp at Mount Everest to study heart disease and aging are at it again, this time in Africa. Along with a party of nearly 35, they will be climbing Mt. Kilimanjaro, obtaining scientific data from the climbers along the way.

Led by Mayo physiologist Bruce Johnson, Ph.D. and joined by Amine Issa, Ph.D., Courtney Wheatley, Ph.D., and Jan Stepanek, M.D., among others, the group will monitor climbers’ heart rates, oxygen saturation, movement, energy expenditure, skin temperature and the quality of their sleep. They’ll also conduct ultrasound scanning to determine differences in younger and older climbers as they react to the altitude.

“It’s about comparing heart and lung function in this natural laboratory,” says Dr. Issa, who was part of the group on Everest. “We want to check on limitations to their functioning and whether or not a vitamin B3 supplement can help them.”

That supplement is being tested as part of Mayo’s collaboration with Thorne Research, a pharmaceutical company, which is a major sponsor of the climb. The researchers want to determine if an analog of vitamin B3 will increase metabolism efficiency and something called NAD – nicotinamide adenine dinucleotide – in the climbers’ blood. If so, it should help them adapt to the rigors of altitude sickness, which is in itself an analog for heart and lung disease.

Mayo will have eight in its research group. Everest mountaineer Conrad Anker of equipment sponsor The North Face, will lead the climb. In addition to Thorne Research, there will be individuals from Philips with equipment and analysis, and Biovotion,– also major equipment providers, – members of documentary production company Seadog — and a team from Griffith University in Australia. Also along will be Linda Wortman, cancer survivor and Mayo Clinic lung surgery patient.

The climbers will arrive in Tanzania on August 4th and begin their ascent on the 7th, to return in ten days. When possible, climbers will be posting their progress on social media via #kiliclimb2016. Kiliminjaro, a range consisting of three dormant volcanoes, is the highest mountain in Africa.

Jun 7, 2016 · Mayo Talks Research at BIO Conference

The Minnesota Pavilion at BIO 2016

The Minnesota Pavilion at BIO 2016

From Taiwan to Texas, anyone who has anything to do with biosciences is here in San Francisco to hear speakers, attend education sessions, but mostly to network and make contacts for business and research. Mayo Clinic is here along with Destination Medical Center in Minnesota to talk about our research activities and make a major announcement later today. Mayo’s research centers are represented in the Minnesota Pavilion at the conference and by several of our scientists and leaders.

We are spreading the word about Mayo being the NIH’s pick for the national biobank . It was announced just before Memorial Day and not many people noticed. It means Mayo will be handling the biobank storage for the government’s Precision Medicine Initiative. Biobanking is essential for research in medical genomics and advancing the future of medicine in the United States. The award comes with a $142 million grant over five years to build and maintain the space and freezer systems to store 35 million samples representing over 1 million research participants. In the words of Mayo Clinic Biobank director Steve Thibodeau, “This is a big deal.”

May 31, 2016 · We’ll bet on Dr. Ansell anytime

AnsellOn May 17, 2016, the U.S. Food and Drug Administration granted accelerated approval to nivolumab (Opdivo®) for the treatment of patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation.

Nivolumab also received a breakthrough therapy designation for the treatment of relapsed or refractory cHL after failure of autologous HSCT and brentuximab vedotin. Nivolumab also has orphan drug status for the treatment of Hodgkin’s lymphoma under FDA’s accelerated approval program.

Much of the credit for these achievements is due to the work of Stephen Ansell, M.D., Ph.D. of Mayo Clinic. Dr. Ansell led a multi-institution phase I clinical trial of nivolumab which found the immune-boosting drug to be a highly effective therapy for Hodgkin’s lymphoma. The study, which appeared in the New England Journal of Medicine in December, 2014 demonstrated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments.

At the time, Dr. Ansell noted, “Nivolumab is a very promising agent that is reasonably well-tolerated and can easily be combined with other agents in the future. He also predicted, “It won’t be long before this particular agent will be approved, and then we will see other studies exploring how to administer it most effectively.”

Nov 9, 2015 · Mayo Rheumatologist Dr. Timothy Niewold Recognized for Achievements in Lupus Research

timothy-niewold-13730541Mayo Clinic rheumatologist Dr. Timothy Niewold has received the Lupus Foundation of America’s Mary Betty Stevens Young Investigator Prize for his research on the autoimmune disease lupus.

Dr. Niewold accepted his award Nov. 8 at a reception held by the foundation to coincide with the American College of Rheumatology’s annual scientific meeting in San Francisco.

Dr. Niewold’s research “is helping us better understand the causes of lupus and its complications, getting us closer to new and improved ways to treat lupus and the organ damage it creates,” says Dr. Gary Gilkeson, professor of medicine/microbiology and immunology at the Medical University of South Carolina and the chair the Lupus Foundation of America’s Medical-Scientific Advisory Council.
Dr. Niewold is also an associate professor of medicine at the Mayo Clinic College of Medicine in Rochester, Minn. His research focuses on the role of genetics and immune system signaling molecules in the development and progression of lupus and his insights are important to the development of personalized therapies for people with lupus.

The Mary Betty Stevens Young Investigator Prize is presented to recognize exceptional achievements by an investigator in the early part of his or her lupus research career. The award was named after the late Dr. Mary Betty Stevens, who was chair of the rheumatology division at the Johns Hopkins University Medical Center. She was the first woman to occupy a division chair at that institution. She also was the director of rheumatology at Good Samaritan Hospital in Baltimore. Dr. Stevens developed the Hopkins-Good Samaritan Rheumatic Disease Unit, which became renowned for clinical research on lupus and vasculitis.

For additional information about the award and the Lupus Foundation of America’s research initiative, please visit lupus.org/research.

Jul 30, 2015 · Stephen Riederer, Ph.D., Elected Fellow of American Association of Physicists in Medicine

Stephen Riederer, Ph.D.

Stephen Riederer, Ph.D.

The American Association of Physicists in Medicine (AAPM) has announced the election of Mayo Clinic’s Stephen Riederer, Ph.D., as a Fellow of the association. The category of Fellow honors members who have distinguished themselves by their contributions in research, education or leadership in the medical physics community. The award was presented at the annual meeting of the AAPM in July.

Dr. Riederer has been the Director of the MR Laboratory and a member of the Physics Division of the Department of Radiology of Mayo Clinic in Rochester since 1988. His research interests are in the technical development of magnetic resonance imaging (MRI). This includes use of the underlying MRI physics, development of new imaging techniques and implementation that addresses clinically important problems. He is also a member of the Mayo Clinic Research Committee, charged with providing oversight and management of research throughout the enterprise, and chair of the Research Finance Subcommittee.

He received the S.M. degree in Nuclear Engineering from MIT in 1975 and the Ph.D. from the Medical Physics Program of the University of Wisconsin – Madison in 1979. He worked from 1980 to 1983 for GE Medical Systems and from 1983 to 1988 at Duke University (Radiology).

AAPM activities include the Editorial Board of Medical Physics (1986-1992) and Chair of the Physics Program of RSNA/AAPM (1996-1998). Dr. Riederer served as President of ISMRM (1994). He was a member of the NIH Diagnostic Radiology Study Section (1989-1993) and of the Scientific Advisory Committee of The Whitaker Foundation (1997-2003) which provided research funding to many young biomedical engineers.

Dr. Riederer has been PI of NIH R01 grants continuously since 1984. He has been principal advisor to over two dozen students earning Ph.D. degrees, many of whom have gone on to careers in medical physics and biomedical engineering. His research areas of interest have been in the imaging physics of x-ray computed tomography, digital subtraction angiography, and magnetic resonance imaging.

Contact Us · Privacy Policy